estriol has been researched along with Chronic Progressive Multiple Sclerosis in 3 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Estriol was also found to alter the cytokine profile of T cells toward Th2 phenotype by up-regulating the production of IL-10 and inhibiting TNFalpha secretion of T cells." | 1.31 | Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. ( Halder, JB; Hong, J; Rivera, VM; Zang, YC; Zhang, JZ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, JA | 1 |
| Soldan, SS | 1 |
| Alvarez Retuerto, AI | 1 |
| Sicotte, NL | 1 |
| Voskuhl, RR | 1 |
| Zang, YC | 1 |
| Halder, JB | 1 |
| Hong, J | 1 |
| Rivera, VM | 1 |
| Zhang, JZ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Combination Trial of Copaxone Plus Estriol in RRMS[NCT00451204] | Phase 2 | 158 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection. (NCT00451204)
Timeframe: 12 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.25 |
| Placebo Capsules Plus Copaxone Injections | 0.48 |
A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection. (NCT00451204)
Timeframe: 24 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.25 |
| Placebo Capsules Plus Copaxone Injections | 0.37 |
(NCT00451204)
Timeframe: 24 months
| Intervention | probability of relapse at 24 months (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 33.3 |
| Placebo Capsules Plus Copaxone Injections | 42.9 |
Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner. (NCT00451204)
Timeframe: 12 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.33 |
| Placebo Capsules Plus Copaxone Injections | 0.61 |
Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner. (NCT00451204)
Timeframe: 24 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.32 |
| Placebo Capsules Plus Copaxone Injections | 0.46 |
(NCT00451204)
Timeframe: 24 months
| Intervention | probability of relapse event at 24 mo (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 40.5 |
| Placebo Capsules Plus Copaxone Injections | 46.9 |
1 review available for estriol and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Emerging therapies for relapsing multiple sclerosis.
Topics: Clinical Trials as Topic; Emergency Treatment; Enzyme Inhibitors; Estriol; Humans; Immunologic Facto | 2009 |
1 trial available for estriol and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymp | 2003 |
1 other study available for estriol and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B.
Topics: Adult; Case-Control Studies; Cell Movement; Cytokines; DNA-Binding Proteins; Estriol; Female; Humans | 2002 |